Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM59VBG)

Drug Name

2-(3-Isobutyl-phenyl)-propionic acid Drug Info

Synonyms

66622-47-7; 2-(3-isobutylphenyl)propanoic acid; m-Isobutyl Ibuprofen; 2-[3-(2-methylpropyl)phenyl]propanoic Acid; 2-(3-Isobutylphenyl)propionic Acid; (2RS)-2-(3-(2-Methylpropyl)phenyl)propanoic acid; (2RS)-2-[3-(2-Methylpropyl)phenyl]propanoic Acid; Ibuprofen specified impurity A [EP]; Ibuprofen Impurity A; alpha-(3-Isobutylphenyl)propionic acid; SCHEMBL66534; alpha-Methyl-3-(2-methylpropyl)phenylacetic acid; CHEMBL187556; Benzeneacetic acid, alpha-methyl-3-(2-methylpropyl)-; CTK5C4963; MolPort-029-294-062; AKOS023890981

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

Cross-matching ID

PubChem CID: 11424295
CAS Number: CAS 66622-47-7
TTD Drug ID: DM59VBG

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Clinical Trial Drug(s)

Discontinued Drug(s)

Investigative Drug(s)

Download the Complete Related Drug List

Drug(s) Targeting C-X-C chemokine receptor type 1 (CXCR1)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[1]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[1]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[2]
SX-682	DMHMG6X	Melanoma	2C30	Phase 1	[3]
INDOPROFEN	DM5QSKN	Gout	FA25	Withdrawn from market	[1]
R-ketoprofen	DMHSUQ1	N. A.	N. A.	Discontinued in Phase 2	[1]
2-(3-Isopropyl-phenyl)-propionic acid	DMUOWNE	Discovery agent	N.A.	Investigative	[1]
2-[3-(1-Phenyl-ethyl)-phenyl]-propionic acid	DMWIUR0	Discovery agent	N.A.	Investigative	[1]
(R)-2-(4-Isobutyl-phenyl)-propionamide	DMBQ0PR	Discovery agent	N.A.	Investigative	[1]
(R)-N-Hydroxy-2-(4-isobutyl-phenyl)-propionamide	DMWRIQG	Discovery agent	N.A.	Investigative	[1]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Drug(s) Targeting C-X-C chemokine receptor type 2 (CXCR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Ibuprofen	DM8VCBE	Dysmenorrhea	GA34.3	Approved	[1]
Clotrimazole	DMMFCIH	Cutaneous candidiasis	1F23.14	Approved	[4]
Reparixin	DMVBA7I	Pancreatic islet transplantation failure	NE84	Phase 3	[1]
SCH-527123	DMPUAOE	Chronic obstructive pulmonary disease	CA22	Phase 2	[5]
SB-265610	DM8TKG5	Asthma	CA23	Phase 2	[6]
AZD-5069	DM3JSFK	Asthma	CA23	Phase 2	[7]
PS-938285	DMHZIFJ	Chronic obstructive pulmonary disease	CA22	Phase 2	[8]
GSK1325756	DMA6RBF	Chronic obstructive pulmonary disease	CA22	Phase 2	[9]
SB-656933	DMCY785	Chronic obstructive pulmonary disease	CA22	Phase 2	[10]
RIST4721	DMA3DKO	Hidradenitis suppurativa	ED92.0	Phase 2	[11]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-X-C chemokine receptor type 1 (CXCR1)	TTMWT8Z	CXCR1_HUMAN	Inhibitor	[1]
C-X-C chemokine receptor type 2 (CXCR2)	TT30C9G	CXCR2_HUMAN	Inhibitor	[1]

------------------------------------------------------------------------------------

References

1	2-Arylpropionic CXC chemokine receptor 1 (CXCR1) ligands as novel noncompetitive CXCL8 inhibitors. J Med Chem. 2005 Jun 30;48(13):4312-31.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Inhibition of MDSC Trafficking with SX-682, a CXCR1/2 Inhibitor, Enhances NK-Cell Immunotherapy in Head and Neck Cancer Models. Clin Cancer Res. 2020 Mar 15;26(6):1420-1431.
4	Mode of action of clotrimazole: implications for therapy. Am J Obstet Gynecol. 1985 Aug 1;152(7 Pt 2):939-44.
5	CXCR2 Antagonist MK-7123.A Phase 2 Proof-of-Concept Trial for Chronic Obstructive Pulmonary Disease.Am J Respir Crit Care Med.2015 May 1;191(9):1001-11.
6	Emerging drugs for the treatment of chronic obstructive pulmonary disease. Expert Opin Emerg Drugs. 2006 May;11(2):275-91.
7	Pharmacological characterization of AZD5069, a slowly reversible CXC chemokine receptor 2 antagonist. J Pharmacol Exp Ther. 2015 May;353(2):340-50.
8	CenterWatch. Drugs in Clinical Trials Database. CenterWatch. 2008.
9	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
10	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
11	A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis. Dermatol Ther (Heidelb). 2021 Dec;11(6):2179-2193.